Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)

NCT06495723 is registered in ClinicalTrials.gov with Xenothera SAS as lead sponsor.

NCT NCT06495723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06495723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open-label, Multi-center Study to Evaluate the Safety and Efficacy of Glyco-humanized Polyclonal Antibody Directed Against Tumoral T Cells, in Patients With Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)
Lead sponsor
Xenothera SAS
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 9, 2024
Completion date
December 31, 2027
Enrollment
54 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cells lymphoma (ptcl)